

## **Emcure Expands Weight Management Therapy Access with Launch of Poviztra®**

- Available in once-weekly pen device in five strengths with starting price ₹8790/- per month
- State-of-the-art pen device for simple and precise dosing

**Pune, December 22, 2025:** Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) today announced the commercial launch of Poviztra®, semaglutide injection, across India. With this launch Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk's Semaglutide injection for weight management. Available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dosing of 2.4 mg, the products will be priced starting ₹8790/- per month (4 weekly doses). It comes in a state-of-the-art pen device that provides the convenience of simple administration of precise dosing.

Semaglutide injection (Poviztra®) is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes and has demonstrated robust real-world use. Globally, the molecule has nearly a decade of market presence, 38 million patient-years\* of exposure, and a strong safety and efficacy profile backed by comprehensive data.<sup>1-4</sup>

*\*Number of people who have used semaglutide multiplied by time on medicine*

Poviztra® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m<sup>2</sup> or greater (obesity) or 27 kg/m<sup>2</sup> or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Poviztra® is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight<sup>1</sup>. In clinical trials, the semaglutide formulation achieved weight loss of more than 20% in many patients.<sup>2</sup>

Speaking on the launch, Satish Mehta - CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, *"India is facing a significant obesity crisis, having nearly 254 million people living with generalised obesity and an additional 351 million living with abdominal obesity.<sup>5</sup> The introduction of Poviztra® marks an important step in expanding equitable access to scientifically validated weight-management solutions. Through our strong distribution capabilities and pan-India reach, we aim to ensure that more patients can benefit from advanced therapies like semaglutide."*

Obesity is linked to over 230 health complications including cardiovascular disease, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease and Alzheimer's disease.<sup>6</sup> With this launch, Emcure Pharma reinforces its commitment to advancing patient access, improving health outcomes, and supporting innovative treatments that address the growing burden of overweight and obesity in India.

For more information, visit [www.winningverobesity.com](http://www.winningverobesity.com)

### **About Emcure Pharmaceuticals Limited:**

*Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas.*

*Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT October 2025. Emcure is present in 70+ countries globally including Europe and Canada.*

**Media Contact:**

Naveen Soni

+91 9870985003

[naveen.soni@emcure.com](mailto:naveen.soni@emcure.com)

**References:**

1. Wegovy® India Prescribing Information As approved 25 Feb 2025
2. Wilding JPH, et al. *N Engl J Med.* 2021;384:989-1002
3. Wharton S et al. *Lancet Diabetes Endocrinol.* 2025 Nov;13(11):949-963
4. Novo Nordisk data on file
5. Anjana RM et al. *The Lancet Diabetes & Endocrinology.* 2023 Jul 1;11(7):474-89
6. Horn et al. *Postgrad Med* 2022;134:359–75